Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
The Lancet. Oncology|October 24, 2023
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Do-Youn Oh, Patricio Yañez, et al.
The Lancet. Oncology|February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
Cancer Discovery|April 2, 2017
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal CancerRobin M J M van Geel, Josep Tabernero, Elena Elez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCTWilliam D Tap, Arun S Singh, Stephen Patrick Anthony, et al.
Nature Medicine|March 30, 2026
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trialZev A Wainberg, Gulam A Manji, Nathan Bahary, et al.
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
JAMA Oncology|September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical TrialKohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal for Immunotherapy of Cancer|January 30, 2026
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinomaEileen M O'Reilly, Christopher R Cabanski, Jaclyn P Lyman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Pageof 14